BRAF and viral infectious disease: Interestingly, the antiviral effect of BRAFV600E inhibitor vemurafenib was not related to the inhibition of the BRAF kinase since the virus infection was efficiently inhibited in a cell line (A549) that does not contain the V600E mutation of BRAF (14).